Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
Actinic Keratosis
Interventions
DRUG

ingenol mebutate

an application a day for three consecutive days in a pre-determined area

DRUG

5% 5-FU

two applications a day for four weeks in a pre-determined area

Trial Locations (1)

05403000

Hospital das Clínicas of the University of São Paulo Medical School (HCFMUSP), São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

University of Sao Paulo

OTHER

NCT02242747 - Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis | Biotech Hunter | Biotech Hunter